Company profile

Tarsier Pharma company profile

Tarsier Pharma is a late clinical-stage company dedicated to the development and commercialization of a breakthrough therapeutic approach for better and safer treatment of autoimmune and inflammatory ocular diseases. The TRS Platform Technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases and is currently being developed as both eye drops and intravitreal injections. Ocular inflammations are a group of diseases affecting the front and back of the eye. Non-infectious anterior and posterior uveitis is the most known ocular inflammatory disease. However, ocular inflammation is a critical underlying mechanism in the pathology of other inflammatory eye diseases, such..... For more information, log in to dureach.com to view the full company profile.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
00001-00010 employees
Revenue range
$1K+
Founded
2016-01-01

Headquarters

Headquarters
Kinvarra, Connacht, Ireland
Country code
IE
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
2
Total equity funding
$3M
Last funding
Grant / $2.4M / 2019-09-18
Last equity funding
Corporate Round / $3M
Investors
2
Lead investors
1
Founders
1
Articles
26

Founders and investors

Founders

Daphne Haim-Langford

Lead investors

Sun Pharmaceutical Industries

Investors

Horizon 2020Sun Pharmaceutical Industries

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.